The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
The inspection was conducted from July 22-25, 2025
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Subscribe To Our Newsletter & Stay Updated
